Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenuePayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Drugs Made In America Acquisition (DMAA) Other Non-Current Assets (2024)

Drugs Made In America Acquisition filings provide 1 years of Other Non-Current Assets readings, the most recent being $545833.0 for Q4 2024.

  • Quarterly Other Non-Current Assets changed N/A to $545833.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $545833.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $545833.0 for FY2024, N/A changed from the prior year.
  • Other Non-Current Assets hit $545833.0 in Q4 2024 for Drugs Made In America Acquisition.
  • Across five years, Other Non-Current Assets topped out at $545833.0 in Q4 2024 and bottomed at $545833.0 in Q4 2024.